<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5509">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03035227</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00003861</org_study_id>
    <nct_id>NCT03035227</nct_id>
  </id_info>
  <brief_title>Catheter Ablation of Arrhythmias to Improve CRT Response</brief_title>
  <acronym>ABLATE-CRT</acronym>
  <official_title>Catheter Ablation of Arrhythmias to Improve CRT Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dhanunjaya Lakkireddy, MD, FACC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test if catheter ablation is better than medication therapy
      at treating arrhythmias originating from the upper and/or lower chambers of the heart in
      order to allow the heart to beat properly.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 23, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Ejection Fraction (EF)</measure>
    <time_frame>90 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bi-ventricular pacing improvement</measure>
    <time_frame>90 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>365Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>365 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital admissions for heart failure exacerbation</measure>
    <time_frame>365 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) class change</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6 minute walk test</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life - SF-36</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">189</enrollment>
  <condition>Arrhythmia, Cardiac</condition>
  <arm_group>
    <arm_group_label>Catheter Ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Catheter ablation procedure of atrial and/or ventricular arrhythmias.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medical management using antiarrhythmic drugs per standard of care of treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter Ablation</intervention_name>
    <description>Catheter ablation of atrial or ventricular arrhythmia. The technique and type of ablation will be at the discretion of the treating electrophysiologists.</description>
    <arm_group_label>Catheter Ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Arrhythmics</intervention_name>
    <description>Anti-Arrhythmic drugs that are deemed to be appropriate for the given participants's arrhythmia by the treating physician.</description>
    <arm_group_label>Medical Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heart failure patients with CRT-D or CRT-P greater than 3 months

          -  Bi-ventricular pacing less than 94% of the time

          -  3 months after CRT-D or CRT-P implantation an EF improvement less than 5%

          -  Presence of one of the following arrhythmias and eligible for catheter ablation:

          -  Atrial fibrillation

          -  Atrial flutter

          -  Supraventricular tachycardia

          -  Premature ventricular contraction burden greater than 30% in a 24-hour period

          -  Ventricular tachycardia

        Exclusion Criteria:

          -  Estimated survival less than one year

          -  Patient unable to make scheduled follow up visits at treating center

          -  Participating in another investigational study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dhanunjaya Lakkireddy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 25, 2017</lastchanged_date>
  <firstreceived_date>January 25, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Dhanunjaya Lakkireddy, MD, FACC</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
